Screener
Crinetics Pharmaceuticals CRNX Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's other income (expense)?
- Crinetics Pharmaceuticals (CRNX) reported other income (expense) of $12.53M in Q1 2026.
- How has Crinetics Pharmaceuticals's other income (expense) changed year-over-year?
- Crinetics Pharmaceuticals's other income (expense) decreased by 14.3% year-over-year, from $14.63M to $12.53M.
- What is the long-term trend for Crinetics Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's other income (expense) has grown at a 439.4% compound annual growth rate (CAGR), from $61K to $51.63M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Crinetics Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude